Asymmetric Immunomodulation in Psoriasis
A Scientific Platform for Multi-JAK/TYK2 Inhibition via Botanical Nanoparticles
Shifting from toxic immune suppression to the homeostatic reprogramming of the body. How we transform complex phytochemical matrices into nanomedical solutions with precise cellular targeting.
Why Asymmetric Immunomodulation? The Failure of Conventional Immunosuppression
In allopathic medicine, the treatment of severe psoriasis and psoriatic arthritis relies on costly biological therapies or synthetic JAK kinase inhibitors (known as Jakinibs). While these synthetic molecules provide temporary relief from skin lesions, they act like a “sledgehammer”: they non-selectively and aggressively block all JAK pathways (including JAK2 and JAK3), disrupting normal hematopoiesis (blood cell production) and compromising antiviral immunity.
Deniplant Biomedicine’s innovation lies in the use of natural, multi-target, asymmetric (allosteric) inhibitors. Our bioactive compounds do not block the enzyme in a blunt, forceful manner. Instead, they bind “asymmetrically” only to the pseudokinase domain of TYK2 and the interface of JAK1. This precise selectivity halts the hyperactive inflammatory signaling of the cytokines IL-23 and IL-17—which are directly responsible for keratinocyte proliferation in psoriasis—while leaving the body’s ability to defend itself against viruses and infections entirely intact.
The Epigenetic Axis: From the TYK2 Receptor to the Intestinal Bioreactor
Psoriasis is not a skin disease; the skin is merely the screen upon which an immune “fire”—originating in the gut—is projected. Our immunomodulation mechanism follows a precise, three-step biological circuit:
Step 1: Allosteric JAK1/TYK2 Calibration
The polyphenol matrix interacts with dendritic cells and hyperactive lymphocytes within the mucous membranes, tempering systemic inflammatory signals without causing hepatic or renal cytotoxicity.
Step 2: Optimized Microbial Fermentation
The unique structure of the extract serves as a high-quality, selective nutrient source for the gut microbiome. Beneficial bacteria metabolize these compounds, synthesizing a substantial quantity of short-chain fatty acids—most notably, pro-homeostatic butyrate.
Step 3: Genetic Reset (Silencing)
Butyrate acts as a secondary epigenetic messenger. It penetrates the nucleus of immune cells, modifies histone acetylation, and “switches off” (silences) the mutant or hyperactive genes responsible for psoriasis (such as the CARD14 gene), while simultaneously activating regulatory T cells (Tregs) that restore immune balance.
Botanical Nanomedicine: The Power of Natural Nanoparticles
Why is a shift to next-generation technology necessary? In their raw state, many anti-inflammatory polyphenols (such as curcumin or quercetin) possess a dense crystalline structure; they are hydrophobic (“water-hating”) and difficult for the body to absorb.
Uniform Self-Assembly
By utilizing green bionanotechnology, we transform raw extracts into natural, uniform botanical nanoparticles. These act like plant-based exosomes, protecting active molecules from gastric acid.
3D Conformational Preservation
The industrial process of freeze-drying (lyophilization) at -40°C removes water through sublimation in an absolute vacuum. This ensures that the three-dimensional shape of the natural ligands is not thermally distorted, keeping their healing properties intact.
Maximum Porosity and Absorption
The resulting freeze-dried powder is highly porous, allowing for instant rehydration within the digestive tract. Its massive contact surface allows the microbiome to ferment it rapidly, quickly triggering an epigenetic anti-psoriasis response.
The Deniplant Translational Program: Technological Evolution
For over 35 years, the renowned Deniplant tea sachets have demonstrated complete remission of all psoriasis lesions for extended periods, achieving the ultimate goal set out in the 2006 European Guidelines for Psoriasis. Our validation stems from thousands of observational studies on actual patients, medically monitored in collaboration with Prof. Dr. Manole Cojocaru.
The current modernization program marks the transition from traditional aqueous infusions (which relied on the patient’s own preparation and steeping time) to standardized nutraceuticals, available as water-soluble liquid oral solutions and freeze-dried instant beverages.
Each dose of the lyophilized nutraceutical will contain an exact, mathematically determined concentration of phyto-active nanoparticles, offering the patient a simple, safe method with an absorption rate up to 10 times higher; this completely eliminates the risk of variation between batches of plant material and paves the way toward international cGMP standards.